Semaglutide, originally developed for type 2 diabetes, has shown remarkable efficacy for weight losswith clinical trials demonstrating average weight reductions of 15-22% over 68 weeks
View image online ( stylized scientific illustration of hormone receptors For patients with type 2 diabetes and established cardiovascular disease, incretin-based therapy that targets both the GLP-1 and GIP gut hormones is associated with significantly greater cardiorenal benefits than therapy that targets GLP-1 alone
Each serving provides 3g of this combination, with 30 servings per bottle
Their primary strategy is to claim that gallbladder complications result from rapid weight loss rather than the drug itself
Many insurance plans now cover Wegovy, and Klinic manages the prior authorization process
Still, if you're a chocolate fan looking for a dessert-worthy post-workout shake, we're pretty confident you'll like this one